Pfizer Research Grant Request for Proposals: Interventional Research Studies of Brentuximab Vedotin-Based Novel Combinations in AITL and PTCL-NOS
Pfizer Inc. seeks proposals for interventional research on brentuximab vedotin-based novel combinations in AITL and PTCL-NOS to advance clinical and scientific understanding.
Funder: Pfizer Inc.
Due Dates: September 17, 2026: Submission Deadline
Funding Amounts: Up to $500,000 per project; 1–2 projects funded; max project length 3 years.
Summary: Supports investigator-sponsored interventional research on brentuximab vedotin-based combination therapies in AITL and PTCL-NOS to address clinical and scientific gaps.
Description
This competitive grant program from Pfizer Inc. seeks investigator-sponsored interventional research studies focused on novel brentuximab vedotin-based combination therapies for angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS). The aim is to generate robust clinical evidence addressing critical gaps in the use of brentuximab vedotin, regardless of CD30 expression. Proposals should emphasize the evaluation of safety and efficacy of innovative combinations with therapies currently available for PTCL, supported by a strong scientific rationale linked to mechanism of action or disease biology. The program is intended to advance understanding and treatment of these hematologic malignancies through original, high-quality research.
